TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants to fourteen new employees. The Compensation Committee approved restricted stock units covering 10,200 shares of common stock, granted on August 5, 2025.
These grants, made under Nasdaq Rule 5635(c)(4), are part of the employees' compensation packages and will vest equally over four years, contingent on continued employment with TELA Bio.
TELA Bio (NASDAQ: TELA), azienda di tecnologie mediche specializzata in soluzioni per la ricostruzione dei tessuti molli, ha annunciato l'approvazione di premi di incentivazione per quattordici nuovi dipendenti. Il Comitato per la Retribuzione ha approvato unità azionarie vincolate pari a 10.200 azioni di capitale sociale, concesse il 5 agosto 2025.
Questi premi, concessi ai sensi della Regola Nasdaq 5635(c)(4), fanno parte dei pacchetti retributivi dei dipendenti e matureranno in parti uguali nell'arco di quattro anni, subordinatamente alla continuazione del rapporto di lavoro con TELA Bio.
TELA Bio (NASDAQ: TELA), empresa de tecnología médica especializada en soluciones para la reconstrucción de tejidos blandos, anunció la aprobación de concesiones de incentivo para catorce nuevos empleados. El Comité de Compensación aprobó unidades de acciones restringidas por un total de 10.200 acciones, otorgadas el 5 de agosto de 2025.
Estas concesiones, realizadas conforme a la Norma Nasdaq 5635(c)(4), forman parte de los paquetes retributivos de los empleados y se consolidarán en partes iguales durante cuatro años, condicionadas a la continuidad en el empleo con TELA Bio.
TELA Bio (NASDAQ: TELA)는 연조직 재건 솔루션을 전문으로 하는 의료기술 회사로서, 14명의 신입 직원에 대한 인센티브 부여 승인을 발표했습니다. 보상위원회는 2025년 8월 5일에 총 10,200주에 해당하는 제한부여주식단위(RSU)의 부여를 승인했습니다.
이 부여는 Nasdaq 규정 5635(c)(4)에 따라 이루어진 것으로, 직원 보상 패키지의 일부이며 4년간 동일한 비율로 취득됩니다(vesting), TELA Bio와의 계속 고용을 조건으로 합니다.
TELA Bio (NASDAQ: TELA), société de technologie médicale spécialisée dans les solutions de reconstruction des tissus mous, a annoncé l'approbation d'attributions incitatives pour quatorze nouveaux employés. Le comité de rémunération a approuvé des unités d'actions restreintes représentant 10 200 actions, attribuées le 5 août 2025.
Ces attributions, effectuées en vertu de la règle Nasdaq 5635(c)(4), font partie des packages de rémunération des employés et seront acquises à parts égales sur quatre ans, sous réserve de la poursuite de l'emploi chez TELA Bio.
TELA Bio (NASDAQ: TELA), ein Medizintechnikunternehmen, das sich auf Lösungen zur Rekonstruktion von Weichgewebe spezialisiert hat, gab die Genehmigung von Einstellungszuwendungen für vierzehn neue Mitarbeiter bekannt. Das Vergütungskomitee genehmigte Restricted Stock Units in Höhe von 10.200 Aktien, gewährt am 5. August 2025.
Diese Zuwendungen, vorgenommen gemäß Nasdaq-Regel 5635(c)(4), sind Teil der Vergütungspakete der Mitarbeiter und werden gleichmäßig über vier Jahre anteilig erworben, vorbehaltlich des fortbestehenden Arbeitsverhältnisses bei TELA Bio.
- None.
- None.
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
What type of inducement grants did TELA Bio (NASDAQ: TELA) announce in August 2025?
How will the TELA Bio restricted stock units vest for new employees?
Under which Nasdaq rule were TELA Bio's inducement grants approved?
How many new employees received TELA Bio's inducement grants in August 2025?
